News

Eli Lilly: Neue Jobs und ... Dazu kommt die gute Anbindung zum Flughafen in Frankfurt, die Deutschland-Zentrale in Bad Homburg sowie der französische Standort des Unternehmens in Fegersheim.
Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...
Eli Lilly and Company (NYSE:LLY) is one of the 17 stocks that Jim Cramer commented on. Cramer showed a positive sentiment toward Eli Lilly and Company (NYSE:LLY), as he remarked, “Eli Lilly ...
On Thursday, Erste Group analysts downgraded Eli Lilly stock (NYSE: NYSE: LLY) from a buy rating to hold.This decision comes amid concerns about the company’s future earnings projections.
Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.
Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare ...
Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.
Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Image source: Getty Images. A big catalyst could be coming soon.
A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.
Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.
Camurus may earn up to $870 million in milestone payments and royalties from the deal. Lilly to develop and commercialize up to four incretin drug compounds globally. Get ahead of Wall Street ...